World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
100
Citations
57560
World Ranking
8121
National Ranking
4211

Evan A. Stein publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Evan A. Stein sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 414 publications — 41st percentile

41% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Evan A. Stein D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Evan A. Stein sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 100 D-Index — 60th percentile

60% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Evan A. Stein is affiliated with Medpace in the United States and has contributed to the fields of Medicine and Economics, Econometrics and Finance. Their research primarily focuses on Lipoproteins and Cardiovascular Health, with additional work in Pharmaceutical Economics and Policy, Cancer related to Lipids and Metabolism, Health Systems and Economic Evaluations, and Diabetes and Cardiovascular Risks.

Their work spans multiple subfields including Surgery, Economics and Econometrics, Cancer Research, Endocrinology, Diabetes and Metabolism, and Genetics. This multidisciplinary approach is reflected in publications across several high-profile journals, with frequent appearances in:

  • Atherosclerosis
  • Journal of the American College of Cardiology
  • JAMA Cardiology
  • The Lancet Diabetes & Endocrinology
  • Journal of clinical lipidology

Some of their most recent papers include:

  • Association of Apolipoprotein B-Containing Lipoproteins and Risk of Myocardial Infarction in Individuals With and Without Atherosclerosis (2021, JAMA Cardiology)
  • Long-Term Evolocumab in Patients With Familial Hypercholesterolemia (2020, Journal of the American College of Cardiology)
  • Long-term efficacy and safety of lerodalcibep in heterozygous familial hypercholesterolaemia: the LIBerate-HeFH trial (2023, European Heart Journal)
  • Efficacy and Safety of Lerodalcibep in Patients With or at High Risk of Cardiovascular Disease (2024, JAMA Cardiology)
  • Reduction in Multiple Cardiometabolic Risk Factors With Combined Olanzapine/Samidorphan Compared With Olanzapine: Post Hoc Analyses From a 24-Week Phase 3 Study (2022, Schizophrenia Bulletin)

Frequent co-authors in their work include:

  • Frederick J. Raal
  • David Kallend
  • Dirk Blom
  • Traci Turner
  • Meral Kayıkçıoğlu

Best Publications

  • Primary Prevention of Acute Coronary Events With Lovastatin in Men and Women With Average Cholesterol Levels: Results of AFCAPS/TexCAPS

    John R. Downs;Michael Clearfield;Stephen Weis;Edwin Whitney

  • Estrogen plus progestin and the risk of coronary heart disease

    JoAnn A E Manson;Judith Hsia;Karen C. Johnson;Jacques E. Rossouw

  • Design of the Women's Health Initiative clinical trial and observational study

    G. Anderson;S. Cummings;L. S. Freedman;C. Furberg

  • Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* trial)

    Peter H Jones;Michael H Davidson;Evan A Stein;Harold E Bays

  • Simvastatin with or without Ezetimibe in Familial Hypercholesterolemia

    John J.P. Kastelein;Fatima Akdim;Erik S.G. Stroes;Aeilko H. Zwinderman

  • Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial.

    Sylvia Wassertheil-Smoller;Susan Hendrix;Marian Limacher;Gerardo Heiss

  • Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management

    Erik S. Stroes;Paul D. Thompson;Alberto Corsini;Georgirene D. Vladutiu

  • Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol

    Evan A. Stein;Scott Mellis;George D. Yancopoulos;Neil Stahl

  • A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia

    Dirk J. Blom;Tomas Hala;Michael Bolognese;Michael J. Lillestol

  • PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2) : a randomised, double-blind, placebo-controlled trial

    Frederick J Raal;Evan A Stein;Robert Dufour;Traci Turner

  • Relation Between Baseline and On-Treatment Lipid Parameters and First Acute Major Coronary Events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS)

    Antonio M. Gotto;Edwin Whitney;Evan A. Stein;Deborah R. Shapiro

  • Inhibition of PCSK9 With Evolocumab in Homozygous Familial Hypercholesterolaemia (TESLA Part B): A Randomised, Double-Blind, Placebo-Controlled Trial

    Frederick J Raal;Narimon Honarpour;Dirk J Blom;G Kees Hovingh

  • Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial

    Evan A Stein;Dan Gipe;Jean Bergeron;Daniel Gaudet

  • Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy.

    James M. McKenney;Michael J. Koren;Dean J. Kereiakes;Corinne Hanotin

  • Implementation of the Women's Health Initiative study design.

    Garnet L. Anderson;Joann Manson;Robert Wallace;Bernedine Lund

  • Low-Density Lipoprotein Cholesterol–Lowering Effects of AMG 145, a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease in Patients With Heterozygous Familial Hypercholesterolemia The Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) Randomized Trial

    Frederick Raal;Rob Scott;Ransi Somaratne;Ian Bridges

  • Successful ex vivo gene therapy directed to liver in a patient with familial hypercholesterolaemia

    Mariann Grossman;Steven E. Raper;Steven E. Raper;Karen Kozarsky;Karen Kozarsky;Evan A. Stein

  • A pilot study of ex vivo gene therapy for homozygous familial hypercholesterolaemia

    Grossman M;Rader Dj;Muller Dw;Kolansky Dm

  • Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia.

    Eli M. Roth;James M. McKenney;Corinne Hanotin;Gaelle Asset

  • Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events

    M.S. Sabatine;R.P. Giugliano;S.D. Wiviott

Frequent Co-Authors

Frederick J. Raal
Frederick J. Raal University of the Witwatersrand
Harold E. Bays
Harold E. Bays Louisville Metabolic and Atherosclerosis Research Center
Christie M. Ballantyne
Christie M. Ballantyne Baylor College of Medicine
Michael H. Davidson
Michael H. Davidson University of Chicago
John J.P. Kastelein
John J.P. Kastelein University of Amsterdam
Daniel Gaudet
Daniel Gaudet University of Montreal
Robert H. Knopp
Robert H. Knopp University of Washington
Marc S. Sabatine
Marc S. Sabatine Brigham and Women's Hospital
Antonio M. Gotto
Antonio M. Gotto Cornell University
Robert P. Giugliano
Robert P. Giugliano Brigham and Women's Hospital

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring medicine as a field opens up numerous pathways beyond traditional MD programs. Many allied health professionals are enhancing their careers with flexible, online education. For example, adn to np bridge programs allow registered nurses with an associate’s degree to advance smoothly into nurse practitioner roles—without stepping away from their current job.

Another growing area is nutrition. By completing online nutrition degrees, students can pursue roles in dietetics, food science, or wellness coaching, conveniently from home at their own pace.

If your interest lies in healthcare leadership, top cahme-accredited mha programs offer a direct route to administrative positions such as hospital manager or healthcare consultant.

For RNs looking to expand their credentials, consider enrolling in rn to bsn with no clinicals programs, which provide academic advancement without the need for additional clinical hours.

These online degree pathways can provide valuable flexibility, making it easier for aspiring healthcare professionals to upskill and advance in their careers.

Best Scientists Citing Evan A. Stein

Trending Scientists

Recently Published Articles